EGFR and nasopharyngeal carcinoma: According to a meta-analysis, addition of anti-EGFR monoclonal antibodies to standard therapy for NPC significantly improved OS (HR, 0.51; 95% CI, 0.39–0.66) compared to standard therapy alone [25].